The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Blocking - Blocking peptide for Anti-Osteoprotegerin antibody (ab9986)
< 0.100 Eu/µg
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. The lyophilized protein is stable for a few weeks at room temperature. Store at -20°C or -80°C. Avoid freeze / thaw cycle. Please see notes section.
Centrifuge the vial prior to opening. Reconstitute in 5 mM
Tris, pH 7.5 to a concentration of 0.1-1.0 mg/ml. Do not
vortex. This solution can be stored at 2-8oC for up to 1
week. For extended storage, it is recommended to further
dilute in a buffer containing a carrier protein (example
0.1% BSA) and store in working aliquots at -20oC to -80o
Osteoclastogenesis inhibitory factor
TNF receptor superfamily member 11b
Tumor necrosis factor receptor superfamily member 11B
Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis.
Highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung.
Involvement in disease
Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD) [MIM:239000]; also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast-mediated skeletal resorption, the disease can be fatal.
Contains 2 death domains. Contains 4 TNFR-Cys repeats.
N-glycosylated. Contains sialic acid residues. The N-terminus is blocked.